Episode Summary
Executive Summary: Dr. Michelle Monger describes how brain cancers, especially diffuse midline gliomas in children, were long a biological black box and how cancer neuroscience has transformed understanding. Her work shows neurons can directly promote tumor growth via synapses, opening new treatments that combine neural-signal disruption with immunotherapy such as GD2-targeting CAR T cells.
Main Topics: From black-box disease to cancer neuroscience (Priority: 5/5): Monger recounts how little was known about brain cancer biology two decades ago and how technological limits hindered study, especially for pediatric diffuse intrinsic pontine glioma/diffuse midline glioma. A patient donation that enabled the first model (Priority: 5/5): A child’s postmortem tumor donation allowed Monger to culture DIPG cells and create the first cell culture and xenograft mouse model, unlocking lab study and drug screening. Why brain tumors are hard to treat (Priority: 5/5): Brain cancers are difficult because of the blood-brain barrier, the need to treat large regions of brain, and the fact that tumor cells behave differently in the brain than in a Petri dish. Neural activity drives tumor growth (Priority: 5/5): Her group found that neuronal activity strongly promotes growth and invasion in multiple gliomas, and that tumor cells form functional synapses with neurons that electrically support cancer progression. Therapeutic opportunities from disrupting signaling (Priority: 4/5): Because tumors use neurotransmitter receptors and ion channels, existing drugs such as anti-seizure, psychiatry, and cardiology medicines may disrupt harmful neural-cancer interactions and improve outcomes. Immunotherapy and CAR T as part of a multi-pronged strategy (Priority: 4/5): Monger discusses GD2-targeting CAR T-cell therapy, which cured mouse models and is now in clinical trials, though stronger results likely require combinations with other approaches. Broader relevance beyond brain cancer (Priority: 4/5): Findings in pediatric brain tumors also apply to glioblastoma, brain metastases, and peripheral cancers, suggesting a wider field of cancer neuroscience with broad therapeutic potential.
Key Arguments: Brain cancers, especially pediatric diffuse midline gliomas, were under-studied because they were hard to access and lacked models for laboratory research. A child’s donated tumor tissue was pivotal in creating the first DIPG culture and xenograft model, proving the disease could be studied experimentally. Cancer biology in a Petri dish is insufficient for brain tumors because the brain environment changes tumor behavior and therapy response. Neurons are not passive neighbors; their activity can powerfully promote glioma growth and invasion. Functional synapses between neurons and tumor cells are a fundamental mechanism of disease progression. Drugs already used for seizures, psychiatric conditions, and heart disease may be repurposed to interrupt tumor-supporting signaling pathways. Retrospective patient data suggest that a particular anti-seizure medication improved outcomes in diffuse midline glioma. CAR T-cell therapy against GD2 produced tumor clearance and cures in mouse models and has shown promising early clinical activity in children. The most realistic path forward is a combination strategy: neural-signal disruption, immunotherapy, and other treatments together. Discoveries in brain cancer are revealing general principles that may help other cancers, including brain metastases and peripheral tumors. The field is moving from hopelessness toward actionable biology, making effective therapies seem increasingly within reach.
Data Points: Time in the field: 20 years - Monger has spent two decades studying how brain tumors form and interact with healthy brain cells. Pediatric DIPG/DMG status: Leading cause of cancer-related death in children - She identifies diffuse intrinsic pontine glioma/diffuse midline glioma as one of the most aggressive pediatric brain cancers. Initial patient survival: Within 6 months - A young girl with DIPG died six months after symptom onset, motivating Monger’s focus on the disease. First model creation: First cell culture and xenograft mouse model of DIPG - Created from a donated postmortem pediatric tumor, enabling experimental study of the cancer. Clinical trial start: Spring 2020 - GD2-targeting CAR T-cell therapy entered clinical trial about six years before the interview. CAR T development timeline: Nearly 10 years ago - Mouse studies showed GD2-targeting CAR T cells could cure tumors in models. Prospective patient evidence: 6 years - Children have been treated with GD2-targeting CAR T-cell therapies over the last six years. Research era mentioned: Early 2000s to 2020 - Describes the period when brain cancer biology and sequencing tools were just emerging.
Pivotal Quotes: "there was really very little understood about the fundamental biology of brain cancers" — Dr. Michelle Monger: She explains the scientific starting point when she entered the field two decades ago. "the activity of neurons ... very powerfully promotes the growth of a wide range of brain cancers" — Dr. Michelle Monger: She summarizes the core discovery that neural activity can drive glioma growth and invasion. "we have to find a solution to these terrible cancers. They deserve better" — Dr. Michelle Monger: Her motivation for continuing the work and pushing toward effective therapies.
Implications: The interview suggests brain cancer treatment will likely improve through combination therapies that target both tumor biology and neuron-tumor communication. It also signals that cancer neuroscience may reshape treatment for multiple cancer types, not just brain tumors.